The U.S. Preventive Services Task Force’s new guidelines to offer mammography from age 40 will save many lives.
The U.S. Preventative Services Task Force has postponed its November meeting due to the federal government shutdown.
The new breast cancer screening guidelines are not enough to save Black women
A breast surgical oncologist and breast radiologist weigh in
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
Chief, Breast Surgical Oncology,
Director, Breast Program, New York Presbyterian Brooklyn Methodist Hospital; Assistant professor of surgery, Weill Cornell Medicine
Director, Breast Program, New York Presbyterian Brooklyn Methodist Hospital; Assistant professor of surgery, Weill Cornell Medicine
Vice chair, Diversity, Equity, and Inclusion,
Department of Radiology, Associate professor of clinical radiology, Weill Cornell Medicine; Associate attending radiologist, New York-Presbyterian Hospital
Department of Radiology, Associate professor of clinical radiology, Weill Cornell Medicine; Associate attending radiologist, New York-Presbyterian Hospital
Table of Contents
YOU MAY BE INTERESTED IN
Paige Aiello has joined The Barbara Ann Karmanos Cancer Institute as a breast surgeon and member of the Breast Cancer Multidisciplinary Team.
Enhertu (fam-trastuzumab deruxtecan-nxki) demonstrated a highly statistically significant and clinically meaningful improvement in invasive disease-free survival in patients with a high risk of disease recurrence, according to results from DESTINY-Breast05 phase III trial.
Positive results from the DESTINY-Breast11 phase III trial showed Enhertu (fam-trastuzumab deruxtecan-nxki) followed by paclitaxel, trastuzumab, and pertuzumab in the neoadjuvant setting demonstrated a statistically significant and clinically meaningful improvement in the pathologic complete response rate.
Two years of adjuvant Verzenio (abemaciclib) plus endocrine therapy reduced the risk of death by 15.8% versus ET alone and resulted in sustained long-term improvements in invasive disease-free survival and distant relapse-free survival, in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive, high-risk early breast cancer, according to the primary overall survival analysis of the phase III monarchE trial.
Armando E. Giuliano will receive the William L. McGuire Memorial Lecture Award during the 2025 San Antonio Breast Cancer Symposium, to be held Dec. 9-12 at the Henry B. Gonzalez Convention Center in San Antonio.
